Ferenc Tracik - 18 Mar 2026 Form 3 Insider Report for NeuroSense Therapeutics Ltd. (NRSN)

Role: Chief Medical Officer
Signature: /s/ Ferenc Tracik
Issuer symbol: NRSN
Transactions as of: 18 Mar 2026
Net transactions value: $0
Form type: 3
Filing time: 18 Mar 2026, 15:36:31 UTC
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Tracik Ferenc	Chief Medical Officer	C/O NEUROSENSE THERAPEUTICS LTD., 11 HAMENOFIM STREET, BUILDING B, HERZLIYA, ISRAEL	/s/ Ferenc Tracik	18 Mar 2026	0002120172

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	NRSN	Ordinary Shares						189,618	18 Mar 2026	Direct
holding	NRSN	Ordinary Shares						428,011	18 Mar 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	NRSN	Options to Purchase Ordinary Shares							18 Mar 2026	Ordinary Shares	108,000	$3.51	Direct	F2
holding	NRSN	Warrants to purchase Ordinary Shares							18 Mar 2026	Ordinary Shares	66,667	$0.7500	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These restricted shares vest in accordance with the following vesting schedule: (i) 75% vest on April 16, 2027, and (ii) the remaining portion shall vest on October 16, 2027, subject to the Reporting Person's continued service to the Issuer as of such vesting date, provided that, the vesting of these restricted shares will accelerate, and the shares will become fully vested and exercisable, upon and subject to the achievement of a certain business milestone as set forth in the restricted share agreement between the Issuer and the Reporting Person.
F2	These options are fully vested and exercisable.
F3	On August 15, 2024, the Reporting Person acquired (i) 66,667 ordinary shares of the Company, no par value per share ("Ordinary Shares"), and (ii) warrants to purchase up to 66,667 Ordinary Shares at a combined purchase price of $0.75 per Ordinary Share and accompanying warrant, in a private placement transaction pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended.